PH24100A - A hydrogel device containing a biologically active agent wherein the active agent concentration profile contains a sigmoidal concentration gradient,for improved constant release and manufacture thereof - Google Patents

A hydrogel device containing a biologically active agent wherein the active agent concentration profile contains a sigmoidal concentration gradient,for improved constant release and manufacture thereof

Info

Publication number
PH24100A
PH24100A PH32244A PH32244A PH24100A PH 24100 A PH24100 A PH 24100A PH 32244 A PH32244 A PH 32244A PH 32244 A PH32244 A PH 32244A PH 24100 A PH24100 A PH 24100A
Authority
PH
Philippines
Prior art keywords
active agent
manufacture
device containing
constant release
profile contains
Prior art date
Application number
PH32244A
Other languages
English (en)
Inventor
Ping I Lee
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of PH24100A publication Critical patent/PH24100A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Cosmetics (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Colloid Chemistry (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
PH32244A 1984-05-10 1985-05-09 A hydrogel device containing a biologically active agent wherein the active agent concentration profile contains a sigmoidal concentration gradient,for improved constant release and manufacture thereof PH24100A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/608,756 US4624848A (en) 1984-05-10 1984-05-10 Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use

Publications (1)

Publication Number Publication Date
PH24100A true PH24100A (en) 1990-03-05

Family

ID=24437841

Family Applications (1)

Application Number Title Priority Date Filing Date
PH32244A PH24100A (en) 1984-05-10 1985-05-09 A hydrogel device containing a biologically active agent wherein the active agent concentration profile contains a sigmoidal concentration gradient,for improved constant release and manufacture thereof

Country Status (16)

Country Link
US (1) US4624848A (fr)
EP (1) EP0164311B1 (fr)
JP (1) JPS619A (fr)
AT (1) ATE61731T1 (fr)
AU (1) AU583507B2 (fr)
CA (1) CA1246447A (fr)
DE (1) DE3582193D1 (fr)
DK (1) DK205185A (fr)
ES (1) ES8603273A1 (fr)
FI (1) FI851801L (fr)
GR (1) GR851114B (fr)
IL (1) IL75129A (fr)
NZ (1) NZ212030A (fr)
PH (1) PH24100A (fr)
PT (1) PT80416B (fr)
ZA (1) ZA853511B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
JPS61218517A (ja) * 1985-03-25 1986-09-29 Bio Materiaru Yunibaasu:Kk 経皮吸収製剤
FR2585246A1 (fr) * 1985-07-26 1987-01-30 Cortial Procede d'obtention de formes pharmaceutiques solides a liberation prolongee
US4794002A (en) * 1985-11-01 1988-12-27 Monsanto Company Modified polymeric surfaces and process for preparing same
JPH0643851B2 (ja) * 1986-03-13 1994-06-08 大同メタル工業株式会社 軸受ユニット
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US4780236A (en) * 1986-06-20 1988-10-25 Kiwi Brands, Inc. Lavoratory cleansing block containing polyethylene gycol disteatrate, guar gum and sodium chloride
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
GB8620845D0 (en) * 1986-08-28 1986-10-08 Reckitt & Colmann Prod Ltd Treatment of textile surfaces
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0297650A1 (fr) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions avec une délivrance contrôlée d'ordre zéro et méthode pour leur préparation
US4910015A (en) * 1987-10-19 1990-03-20 Massachusetts Institute Of Technology Surface-active polysiloxanes and drug releasing materials thereof
GB8801863D0 (en) * 1988-01-28 1988-02-24 Fulmer Yarsley Ltd Pharmaceutical formulations with controlled drug release
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
DE19843904A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit polymerem Bindemittel
DE19843903A1 (de) * 1998-09-24 2000-03-30 Basf Ag Feste Dosierungsform mit copolymerem Bindemittel
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
CN1402632A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 水凝胶驱动的药物剂型
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
GB0027357D0 (en) * 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
PT1409065E (pt) 2001-07-23 2007-03-30 Alcon Inc Dispositivo de administração de fármacos oftálmicos
PT1385452E (pt) * 2001-07-23 2006-12-29 Alcon Inc Dispositivo de administração de fármacos oftálmicos
CA2464653C (fr) * 2001-10-29 2011-10-18 Therics, Inc. Systeme d'elaboration de formes pharmaceutiques a liberation controlee, du type forme pharmaceutique a profil de liberation d'ordre zero elaboree en impression tridimensionnelle
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
GB0310636D0 (en) * 2003-05-08 2003-06-11 Nektar Therapeutics Uk Ltd Particulate materials
CA2524773C (fr) 2003-05-08 2014-04-08 Nektar Therapeutics Uk Ltd Coformulations particulaires de substances actives comprenant des excipients
CN1805719A (zh) * 2003-07-10 2006-07-19 爱尔康公司 眼药输送装置
US20060246109A1 (en) * 2005-04-29 2006-11-02 Hossainy Syed F Concentration gradient profiles for control of agent release rates from polymer matrices
US8153162B2 (en) 2005-09-27 2012-04-10 Tissuetech, Inc. Purified amniotic membrane compositions and methods of use
US8187639B2 (en) * 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
EP1959966B1 (fr) 2005-11-28 2020-06-03 Marinus Pharmaceuticals, Inc. Formes galéniques de ganaxolone et procédés de preparation et d'utilisation de celles-ci
US8246973B2 (en) 2006-06-21 2012-08-21 Advanced Cardiovascular Systems, Inc. Freeze-thaw method for modifying stent coating
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
WO2008021368A2 (fr) 2006-08-11 2008-02-21 The Johns Hopkins University Compositions et méthodes de neuroprotection
EP2532235A1 (fr) 2006-09-22 2012-12-12 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de bruton
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
WO2009073734A2 (fr) 2007-12-03 2009-06-11 Medipacs, Inc. Dispositif de mesure de fluide
WO2010027875A2 (fr) 2008-08-27 2010-03-11 Calcimedica Inc. Composés qui modulent le calcium intracellulaire
ES2559029T3 (es) 2009-04-24 2016-02-10 Tissue Tech, Inc. Composiciones que contienen al complejo HC.HA y metodos de uso de las mismas
WO2011032011A1 (fr) 2009-09-10 2011-03-17 Medipacs, Inc. Actionneur à faible encombrement et méthode améliorée d'administration d'agents thérapeutiques commandée par le soignant
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
ES2602475T3 (es) 2010-04-15 2017-02-21 Tracon Pharmaceuticals, Inc. Potenciación de la actividad anticáncer por terapia de combinación con inhibidores de la vía BER
PL2563776T3 (pl) 2010-04-27 2017-01-31 Calcimedica Inc Związki, które modulują wewnątrzkomórkowy wapń
US8754219B2 (en) 2010-04-27 2014-06-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA3240281A1 (fr) 2010-06-03 2011-12-08 Pharmacyclics Llc Utilisation d'inhibiteurs de la tyrosine-kinase de bruton dans le traitement du lymphome folliculaire
CN103180316A (zh) 2010-08-27 2013-06-26 钙医学公司 调节细胞内钙的化合物
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
WO2012170905A1 (fr) 2011-06-10 2012-12-13 Tissuetech, Inc. Procédés de traitement de tissus fœtaux de support, produits en poudre à base de tissu fœtal de support et leurs utilisations
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
CN104302689A (zh) 2012-03-14 2015-01-21 麦德医像公司 含有过量活性分子的智能聚合物材料
CN104736178A (zh) 2012-06-04 2015-06-24 药品循环公司 布鲁顿酪氨酸激酶抑制剂的晶形
CA2878163A1 (fr) 2012-07-11 2014-01-16 Tissuetech, Inc. Compositions contenant des complexes hc-ah/ptx3 et procedes d'utilisation associes
DK2900674T3 (en) 2012-09-28 2017-07-03 Univ Washington Through Its Center For Commercialization RELATIONSHIPS AND PROCEDURES FOR PREVENTION, TREATMENT AND / OR PROTECTION AGAINST SENSITIVE CELL DEATH
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
WO2015164213A1 (fr) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York Réaction de ligature bio-orthogonale rapide et efficace et hétérocycles contenant du bore utiles en association avec celle-ci
TW201603818A (zh) 2014-06-03 2016-02-01 組織科技股份有限公司 組成物及方法
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA2974395C (fr) 2015-02-06 2023-08-22 University Of Washington Composes et procedes pour prevenir ou traiter la mort de cellules capillaires sensorielles
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160243288A1 (en) 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
CA2977521C (fr) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. Composes d'uree 1-(aryle)-3-(heteroaryle) et utilisation comme inhibiteurs du facteur olig2
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
MA41827A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA41828A (fr) 2015-03-27 2018-01-30 Pharmacyclics Llc Co-cristaux d'un inhibiteur de la tyrosine kinase de bruton
CN113413387A (zh) 2015-05-11 2021-09-21 H.隆德贝克有限公司 治疗炎症或神经性疼痛的方法
JP2018516869A (ja) 2015-05-20 2018-06-28 ティッシュテック,インク. 上皮細胞の増殖および上皮間葉転換を防ぐための組成物および方法
CN108135904A (zh) 2015-08-31 2018-06-08 药品循环有限责任公司 用于治疗多发性骨髓瘤的btk抑制剂组合
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
WO2017100861A1 (fr) 2015-12-16 2017-06-22 The Walter And Eliza Hall Institute Of Medical Research Inhibition de protéines sh2 induites par des cytokines dans des cellules nk
WO2017125424A1 (fr) 2016-01-19 2017-07-27 Janssen Pharmaceutica Nv Formulations/compositions comprenant un inhibiteur de btk
CN108472259A (zh) 2016-01-19 2018-08-31 詹森药业有限公司 包含btk抑制剂的配制品/组合物
TW201733600A (zh) 2016-01-29 2017-10-01 帝聖工業公司 胎兒扶持組織物及使用方法
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
WO2017176652A2 (fr) 2016-04-04 2017-10-12 Sinopia Biosciences, Inc. Traitement de syndrome extrapyramidal à l'aide de trapidil
EP3463576A4 (fr) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. Promédicaments à base d'agonistes de trpv1 phénoliques en association avec des anesthésiques locaux et des vasoconstricteurs pour améliorer une anesthésie locale
WO2017205766A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine-1
WO2017205762A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
WO2017205769A1 (fr) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibiteurs de la kinase associée au récepteur de l'interleukine 1
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
US11090702B2 (en) * 2016-06-28 2021-08-17 Trustees Of Tufts College Compositions and methods for delivery of active agents
CA3030821A1 (fr) 2016-07-18 2018-01-25 Arthrosi Therapeutics, Inc. Composes, compositions et methodes de traitement ou de prevention d'un symptome associe a la goutte ou a l'hyperuricemie
AU2017314842B9 (en) 2016-08-26 2022-02-10 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
MA46866B1 (fr) 2016-11-16 2021-11-30 H Lundbeck As Une forme cristalline d'un inhibiteur de magl
AU2017361254B2 (en) 2016-11-16 2021-09-23 H. Lundbeck A/S. Pharmaceutical formulations
WO2019046731A1 (fr) 2017-09-01 2019-03-07 University Of Washington Formes cristallines de composés pour prévenir ou traiter la mort de cellules ciliées sensorielles
WO2019169112A1 (fr) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition de l'activité d'olig2
JP2021532183A (ja) 2018-07-27 2021-11-25 コンセントリック アナルジェジクス,インク. フェノール性trpv1アゴニストのpeg化プロドラッグ
KR20210117261A (ko) 2018-12-31 2021-09-28 바이오메아 퓨전, 인크. 메닌-mll 상호작용의 비가역적 억제제
CA3133093A1 (fr) 2019-03-15 2020-09-24 Unicycive Therapeutics, Inc. Derives de nicorandil
CN115427403A (zh) 2020-04-21 2022-12-02 H.隆德贝克有限公司 单酰基甘油脂肪酶抑制剂的合成
WO2022133064A1 (fr) 2020-12-16 2022-06-23 Biomea Fusion, Inc. Composés de pyrimidine fusionnée utilisés comme inhibiteurs de l'interaction ménine-mll
WO2022150525A1 (fr) 2021-01-06 2022-07-14 Awakn Life Sciences Mdma dans le traitement d'un trouble de consommation d'alcool
CA3218884A1 (fr) 2021-05-11 2022-11-17 David Nutt Composes et compositions therapeutiques a base d'aminoindane
EP4346788A2 (fr) 2021-06-03 2024-04-10 Arcadia Medicine, Inc. Compositions entactogènes énantiomères et leurs méthodes d'utilisation
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
AU2022331496A1 (en) 2021-08-20 2024-02-29 Biomea Fusion, Inc. Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer
WO2023028091A1 (fr) 2021-08-23 2023-03-02 Alexander Shulgin Research Institute Empathogènes deutérés
WO2023027966A1 (fr) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Composés de pyrazine en tant qu'inhibiteurs irréversibles de flt3
WO2023039240A1 (fr) 2021-09-13 2023-03-16 Biomea Fusion, Inc. Inhibitors irréversibles de kras
WO2023086341A1 (fr) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibiteurs de kras
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023139163A1 (fr) 2022-01-19 2023-07-27 Awakn Ls Europe Holdings Limited Esters de 1,3-benzodioxole et leur utilisation thérapeutique
WO2023156565A1 (fr) 2022-02-16 2023-08-24 Awakn Ls Europe Holdings Limited Composes cycliques pontés et leur utilisation thérapeutique comme agents du snc
WO2023235618A1 (fr) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Composés de pyrimidine fusionnés en tant qu'inhibiteurs de la ménine
WO2024011142A1 (fr) 2022-07-06 2024-01-11 Oppilan Pharma Limited Formes cristallines d'un modulateur du récepteur s1p
WO2024155719A1 (fr) 2023-01-18 2024-07-25 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phényl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-pipéridinyl]méthyl]-2- pyridinecarboxamide en tant qu'inhibiteur covalent de l'interaction ménine-mll

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH468192A (de) * 1964-06-19 1969-02-15 Ciba Geigy Verfahren zur Herstellung von Arzneimitteln in Perlenform
IT1050353B (it) * 1966-01-06 1981-03-10 Ceskoslovenska Akademie Ved Supporti per sostanze biologigamente attive
US3660563A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a drug
US3660071A (en) * 1966-07-26 1972-05-02 Nat Patent Dev Corp Water soluble entrapping of a pesticide
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3576760A (en) * 1969-06-13 1971-04-27 Nat Patent Dev Corp Water soluble entrapping
DE2031871C3 (de) * 1970-06-27 1974-06-27 Roehm Gmbh, 6100 Darmstadt Überzugsmasse für Arzneiformen
GB1394990A (en) * 1971-08-12 1975-05-21 Hydrophilics Int Inc Copolymers and compositions containing copolymers
US4056496A (en) * 1972-10-02 1977-11-01 Corneal Sciences, Inc. Hydrogels and articles made therefrom
US4070348A (en) * 1973-07-25 1978-01-24 Rohm Gmbh Water-swellable, bead copolymer
US4178361A (en) * 1973-09-10 1979-12-11 Union Corporation Sustained release pharmaceutical composition
US4007258A (en) * 1973-09-10 1977-02-08 Union Corporation Sustained release pesticidal composition
CH621561A5 (en) * 1974-01-14 1981-02-13 Ceskoslovenska Akademie Ved Process for producing a bromocyan-activated, hydrophilic, polymeric carrier for biologically active compounds in dried form
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US4248855A (en) * 1976-08-27 1981-02-03 Hydrophilics International, Inc. Pharmaceutical base salts
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4304591A (en) * 1978-01-25 1981-12-08 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
CA1125698A (fr) * 1978-03-09 1982-06-15 Masaru Yoshida Methode de preparation d'une composition a base de polymere
US4267295A (en) * 1979-02-09 1981-05-12 Syntex (U.S.A.) Inc. Polymeric compositions and hydrogels formed therefrom
US4357312A (en) * 1981-07-16 1982-11-02 The Children's Hospital Medical Center Method of making prolonged release body
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
GB8319766D0 (en) * 1983-07-22 1983-08-24 Graham N B Controlled release device

Also Published As

Publication number Publication date
EP0164311A2 (fr) 1985-12-11
CA1246447A (fr) 1988-12-13
ATE61731T1 (de) 1991-04-15
DK205185A (da) 1985-11-11
IL75129A0 (en) 1985-09-29
FI851801L (fi) 1985-11-11
JPS619A (ja) 1986-01-06
ES542948A0 (es) 1986-01-01
ZA853511B (en) 1985-12-24
US4624848A (en) 1986-11-25
NZ212030A (en) 1988-01-08
DK205185D0 (da) 1985-05-09
EP0164311B1 (fr) 1991-03-20
EP0164311A3 (en) 1987-06-03
PT80416B (en) 1987-04-16
GR851114B (fr) 1985-11-25
ES8603273A1 (es) 1986-01-01
PT80416A (en) 1985-06-01
DE3582193D1 (de) 1991-04-25
FI851801A0 (fi) 1985-05-08
AU4221685A (en) 1985-11-14
IL75129A (en) 1989-08-15
AU583507B2 (en) 1989-05-04

Similar Documents

Publication Publication Date Title
PH24100A (en) A hydrogel device containing a biologically active agent wherein the active agent concentration profile contains a sigmoidal concentration gradient,for improved constant release and manufacture thereof
DE3581673D1 (de) Abgabevorrichtung zur freisetzung nullter ordnung eines wirkstoffes in eine loesende fluessigkeit, sowie verfahren zu deren herstellung.
ES2001897A6 (es) Procedimiento para la fabricacion de una tableta de liberacion controlada
DK0432607T3 (da) Tabletter med reguleret frigivelseshastighed for aktive stoffer
DK0417572T3 (da) Forlænget frigivelse af små vandopløselige molekyler
GB2146531B (en) Controlled release system
ES2194232T3 (es) Reservorio de espuma polimerica para dispositivo de aporte por electrotransporte.
ATE68686T1 (de) System zum freigeben von stoffen in der vagina.
ES8305583A1 (es) Un procedimiento para la produccion de un dispositivo para la administracion controlada y continua de un producto quimi-co particularmente farmacos, a un entorno que contiene un liquido acuoso.
DE3862788D1 (de) Fluessige oxydationsmodifizierte ethylenische statistische copolymere, verfahren zur herstellung und deren verwendung.
JPS52130980A (en) Immobilization of glucoseisomerase
Obermayer Toxic-Monitoring Badge and Method of Use
MX5150E (es) Procedimiento para preparar un copolimero de bloque hidrofilico que contiene un agente biologicamente activo